Business Context and Reporting Period
This Form 8-K is filed by AmerisourceBergen Corporation (now Cencora, Inc.) on August 3, 2017. The report announces the results of operations for the fiscal quarter ended June 30, 2017, and discloses significant regulatory developments regarding a criminal investigation.
Key Financial Metrics and Material Changes
The filing does not provide specific revenue, profit, cash flow, or margin figures for the quarter; these details are contained in the attached news release (Exhibit 99.1) which is incorporated by reference. However, the filing discloses a specific material financial impact:
- Unusual Item: The Company recorded a litigation reserve of $260.0 million in "Employee Severance, Litigation, and Other" on the Consolidated Statements of Operations for the three and nine months ended June 30, 2017.
- Debt and Liquidity: The filing text does not provide specific values for debt or liquidity positions.
Guidance, Outlook, Risks, and Contingencies
Regulatory Proceedings: The Company's subsidiary, AmerisourceBergen Specialty Group (ABSG), reached an agreement in principle with the U.S. Attorney's Office for the Eastern District of New York (USAO-EDNY) to resolve a criminal investigation dating back to fiscal 2012. The investigation concerned the pre-filled syringe program of Medical Initiatives, Inc. (which ceased operations in 2014).
- Criminal Resolution: ABSG will plead guilty to a strict liability misdemeanor under the Federal Food, Drug and Cosmetic Act and pay $260.0 million. The Company will enter into a Compliance Agreement with the Department of Justice. Final terms are subject to court approval.
- Civil Claims: The USAO-EDNY intends to pursue alleged civil claims under the False Claims Act. Discussions are ongoing, but significant disagreements exist. The Company states it is unable to reasonably estimate a range of loss for the civil matter and no conclusion can be drawn regarding the likely outcome.
- Outlook: The Company intends to vigorously defend itself against the civil claims. Any settlement or resolution of the civil matter could have an adverse effect on business, results of operations, or cash flows.
Investor Verification Checklist
- Verify the full financial results (revenue, net income, EPS) in the attached news release (Exhibit 99.1) as they are not detailed in the 8-K text.
- Confirm the final execution of the $260.0 million criminal settlement and the terms of the Compliance Agreement with the DOJ.
- Monitor the status of the ongoing civil False Claims Act discussions to assess potential additional liabilities beyond the $260.0 million reserve.
- Review the conference call slides and transcript for management commentary on the impact of the litigation reserve on future guidance.